Cabrera ÁG, Gómez-Galicia D, Rodríguez-Fragoso L, Madrid MV, Cañedo DL, Sánchez-Alemán M, Méndez-Sánchez N, Reyes EJ

Idioma: Ingles.
Referencias bibliográficas: 38
Paginas: 458-468
Archivo PDF: 745.98 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Modi AA, Liang TJ. Hepatitis C: a clinical review. Oral Dis 2008; 14: 10-4.

2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

3. Negro F. Adverse effects of drugs in the treatment of viral hepatitis, Best Pract Res Clin Gastroenterol 2010; 24: 183-92.

4. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273-9.

5. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon alpha. Gastroenterology 2002; 123: 41-51.

6. Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 1424-9.

7. Wenzel F, Gruber W, Giers G. Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy. Clin Hemorheol Microcir 2010; 44(2): 137-44.

8. Maloisel F, Andrès E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 2004; 116: 590-4.

9. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004; 79: 504-22.

10. Ahn YS, Rocha R, Mylvaganam R, et al. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med 1989; 111: 723-9.

11. Mylvaganam R, Ahn YS, Garcia RO, et al. Very low dose danazol in idiopathic thrombocytopenic purpura and its role as an immune modulator. Am J Med Sci 1989; 298: 215 20.

12. Nakhoul IN, Kozuch P, Varma M. Management of adult idiopathic thrombocytopenic purpura. Clin Adv Hematol Oncol 2006; 4: 136-44.

13. Andrés E, Zimmer J, Noel E, et al. Idiopathic thrombocyopenic purpura. A retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol. Drugs Aging 2003; 20: 841-6.

14. Cabrera-Álvarez G, Madrid-Marina V, Jimenez-Mendez R, et al. Combined therapy with danazol, pegilated interferon, and ribavirin improves thrombocytopenia and liver injury in rats with fibrosis. Ann Hepatol 2007; 6: 233-41.

15. World Health Organization. Declaration of Helsinki. Bull World Health Organizat 2001; 79: 373-4.

16. World Health Organization. Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. WHO Technical Reports Series 1995; 850.

17. Melero J, Berenguer M. Antiviral therapy in patients with HCV-cirrhosis. Ann Hepatol 2009; 8: 292-7.

18. Cheng WS, Roberts SK, McCaughan G, et al; on behalf of the CHARIOT Study Group. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010; 53: 616-23.

19. Lacobellis A, Ippolito A, Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008; 14: 6467-72.

20. Demirturk N, Cevik F, Demirdal T, et al. Autoimmune thrombocytopenia induced by PEG-IFN-alpha plus ribavirin in hepatitis C. Platelets 2006; 17: 340-3.

21. Medeiros BC, Seligman PA, Everson GT, et al. Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavirin treatment for hepatitis C. J Clin Gastroenterol 2004; 38: 84-6.

22. Weitz IC. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. Am J Hematol 2005; 78: 138-41.

23. Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. Saudi J Gastroenterol 2010; 16: 51-6.

24. Cook L, Cooper N. Eltrombopag-a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations. Drug Design Develop Ther 2010; 4: 139-45.

25. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-47.

26. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al.; TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-36.

27. Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis 2010; 4: 181-94.

28. Narciso-Schiavon JL, Schiavon LL, Carvalho-Filho RJ, et al. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop 2010; 43: 217-23.

29. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000; 95: 2936-9.

30. Kobayashi M, Ikeda K, Hosaka T, et al. Natural history of compensated cirrhosis in the Child-Pug Class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006; 78: 459-65.

31. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000; 14: 60D-66D.

32. Sallah S, Bobzien W. Bleeding problems in patients with liver disease. Ways to manage the many hepatic effects on coagulation. Postgrad Med 1999; 106: 187-195.

33. Davis GL, Estevan-Mur R, Rustgi V, et al. Interferon Alfa- 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.

34. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver diseases. J Hepatol 2008; 48: 1000-7.

35. Wekler BB. The pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007; 26: 13-9.

36. Ahn YS, Horstman LL. Idiopathic thrombocytopenic purpura: pathophysiology and management. Int J Hematol 2002; 76: 123-31.

37. Masuzaki R, Yoshida H, Omata M. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Oncology 2010; 78: 17-23.

38. McHutchinson JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype- 1 infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.